Who is sponsoring NCT05206175?

NCT05206175 is sponsored by Affect Therapeutics, Inc..

What drugs are being tested in NCT05206175?

Interventions in NCT05206175: Affect Treatment Program for Methamphetamine Use Disorder.

What condition does NCT05206175 study?

NCT05206175 studies Methamphetamine Abuse.

Is NCT05206175 still recruiting?

NCT05206175 is currently completed. Last updated 11 January 2023.

Last reviewed 2023-01-11 · How we verify

NCT05206175

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Demonstration of a Digital Care Program for Methamphetamine Use Disorder

Completed NA Last updated 11 January 2023

What this trial tests

NA trial testing Affect Treatment Program for Methamphetamine Use Disorder in Methamphetamine Abuse in 100 participants. Completed in 31 December 2022.

Timeline

14 February 2022

Primary endpoint
14 November 2022

31 December 2022

Quick facts

Lead sponsor	Affect Therapeutics, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	14 February 2022
Primary completion	14 November 2022
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

Affect Treatment Program for Methamphetamine Use Disorder

Conditions studied

Methamphetamine Abuse — all drugs for Methamphetamine Abuse →

Sponsor

Affect Therapeutics, Inc.

Who can join

18 and older, any sex, with Methamphetamine Abuse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase I Small Business Innovation Research (SBIR) project will examine the technical merit and real-world feasibility of the Affect smartphone application ("app") as the core component of the Affect digital care program for treatment of methamphetamine use disorder (MUD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Methamphetamine Abuse

Currently open trials in the same condition.

NCT06721494 — A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamin · Phase 2 · recruiting
NCT06496750 — Ketamine for Methamphetamine Use Disorder · Phase 2 · recruiting
NCT06410196 — Mood and Decision-making in Methamphetamine Use Disorder · NA · recruiting
NCT06233799 — Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder · Phase 3 · recruiting
NCT05700994 — Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM) · NA · active not recruiting

Other Affect Therapeutics, Inc. trials

Trials by the same sponsor.

NCT05266716 — Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05206175 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Affect Therapeutics, Inc.
Last refreshed: 11 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05206175.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing